Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment for $850M Cash and Earnout Consideration
Johnson & Johnson (NYSE:JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated